Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06002802
Other study ID # TTU 07.905/07.909
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2016
Est. completion date August 31, 2020

Study information

Verified date August 2023
Source Technical University of Munich
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational clinical study aims at the identification of novel biomarkers and causative factors of complicated and/or protracted Epstein-Barr virus-associated infectious mononucleosis (IM). Clinical, biochemical, and routine virological data were collected from 200 patients with IM, novel analytical tools were implemented, and immunological and virological experimental data were generated using blood samples and mouthwashes. Patients have been investigated within four weeks after the onset of symptoms as well as one month and six months thereafter.


Description:

EBV-associated diseases are a severe and global health problem, and novel tools and targets for a better pathogenetic understanding, diagnosis, treatment, and prevention are clearly needed. Here we propose to use several novel experimental approaches to investigate immunological, virological, biochemical, and clinical features in an observational study on Munich IM patients. This study aims at identifying biomarkers and causative factors of protracted and/or complicated IM to facilitate the development of novel approaches to early diagnosis, therapy, and prevention of severe, life-threatening, and chronic EBV-associated diseases, including post-viral syndromes. Two hundred patients with IM onset within the last four weeks were recruited from Munich health care institutions and were re-investigated at one and six months after the onset of symptoms. A novel diagnostic scoring system was developed to indicate the severity, complexity, and protraction of symptoms. Investigated clinical parameters, including reported symptoms and physical signs of IM, as well as candidate risk factors in the medical history of patients and family members. Peripheral blood was analysed by established and novel analytical assays to determine the immunological and virological phenotypes of IM, and viral load was determined in mouthwashes.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date August 31, 2020
Est. primary completion date August 31, 2020
Accepts healthy volunteers No
Gender All
Age group 0 Years to 39 Years
Eligibility Inclusion Criteria: - IM onset within the last four weeks - with at least one of four typical clinical findings (tonsillopharyngitis, fever, lymphadenopathy, fatigue) - virological findings indicating primary EBV infection (EBV-specific antibodies, EBV DNA). Exclusion Criteria: - Pregnancy - transfusion - and/or transplantation during the last year - and/or no informed consent.

Study Design


Locations

Country Name City State
Germany MRI Chonic Fatigue Center for Young People (MCFC), Children's Hospital, Technical University of Munich & Munich Municipal Hospital Munich Bavaria

Sponsors (7)

Lead Sponsor Collaborator
Technical University of Munich German Cancer Research Center, German Center for Infection Research, Hannover Medical School, Helmholtz Zentrum München, Ludwig-Maximilians - University of Munich, University Hospital Freiburg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity Maximal severity of symptoms during the course of IM according the the IMMUC-Score. Six months
Primary Complexity Maximal complexity of symptoms during the course of IM according the the IMMUC-Score Six months
Primary Protraction Maximal protraction of symptoms during the course of IM according the the IMMUC-Score. Six months
Secondary Immune status Cellular and humoral immune status, EBV viral load, antibodies against EBV proteome. Within four weeks post symptom onset and at one and six months thereafter.
See also
  Status Clinical Trial Phase
Completed NCT01256853 - Modified Vaccinia Ankara (MVA) Vaccine Study Phase 1
Completed NCT00070785 - Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations N/A
Recruiting NCT01248598 - The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis N/A
Completed NCT00701922 - Surveillance Study of Viral Infections Following Lung Transplantation N/A
Recruiting NCT02580539 - A Study of the Safety and Efficacy of EBV Specific T-cell Lines Phase 1/Phase 2
Completed NCT03546101 - Early Detection of Epstein-Barr Virus Related Disease.
Recruiting NCT05183490 - R-MVST Cells for Treatment of Viral Infections Phase 1
Completed NCT00058812 - Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts Phase 1
Completed NCT01094405 - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Phase 2
Terminated NCT05305040 - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Completed NCT02335437 - Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents N/A
Recruiting NCT04507477 - Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial Phase 1/Phase 2
Recruiting NCT03266653 - EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection Phase 2
Completed NCT00963248 - EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients N/A
Enrolling by invitation NCT06027879 - Anti-viral T-cell Therapy by Gamma Capture Phase 1/Phase 2
Recruiting NCT05592626 - A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02715752 - A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin N/A
Completed NCT01070797 - Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) Phase 1
Completed NCT00058604 - Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). Phase 1
Completed NCT00058591 - Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) Phase 1